NCT05593666View on ClinicalTrials.gov

A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

December 27, 2022

Primary Completion Date

July 28, 2025

Study Completion Date

December 30, 2025

Conditions
Primary Visceral Leishmaniasis
Interventions
DRUG

LXE408

Film-coated tablets

OTHER

Placebo

Placebo film-coated tablets

DRUG

AmBisome®

Sterile lyophilised powder in a 15 mL sterile clear glass vial

Trial Locations (2)

Unknown

DrugsNeglectedD Investigational Site, Bihār

DrugsNeglectedD Investigational Site, Patna

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Drugs for Neglected Diseases

OTHER

NCT05593666 - A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis | Biotech Hunter | Biotech Hunter